Functional Electrical Stimulation Cycling for Managing Mobility Disability in People with Multiple Sclerosis

Launched by UNIVERSITY OF OTTAWA · May 10, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help people with multiple sclerosis (MS) improve their mobility, which often becomes a challenge for them. The focus is on a method called functional electrical stimulation (FES) cycling, which uses electrical signals to help muscles move while riding a stationary bike. Researchers want to see if this type of exercise can help manage mobility issues and improve quality of life for those living with MS.

To participate in the trial, individuals must be diagnosed with MS, have had no relapses in the past 30 days, and have been stable on their medications for the last six months. They should also be able to communicate in English and be willing to travel to the University of Ottawa for testing and training sessions. Participants will engage in FES cycling sessions and will be monitored for their progress. It’s important to note that certain health conditions, like having a pacemaker or epilepsy, may prevent someone from joining the study. Overall, this trial aims to explore a promising new approach to enhancing mobility for people with MS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosis of multiple sclerosis
• • relapse free in the past 30 days
• • stable course of disease-modifying therapies over the past 6 months
• • ability to communicate in English
• • willing to come to the University of Ottawa to complete testing and training sessions
• • EDSS score 5.0 - 7.0
• • asymptomatic based on a physical activity pre-participation screening tool
• Exclusion Criteria:
• • presence of any contraindication to FES including epilepsy, a pacemaker, implanted defibrillator, unstable fracture, or pregnancy
• • diagnosis of other neurological condition(s)
• • participation in FES cycling exercise or other mobility-based exercise rehabilitation program within the past 6 months
• • current use of dalfampridine within the past month